# US 2024/0189456 A1 · Treatment Of Prion Diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189456 A1
- Document ID: US20240189456A1
- Status: Published application
- Kind: A1
- Application number: 18/535,105
- Filed: 2023-12-11
- Published: 2024-06-13
- Earliest claimed: 2022-12-12
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Sahar Gelfman; Andreja Avbersek; Sarah Wolf; Alicia Hawes; Giovanni Coppola; Vijay Kumar Manickavasagam Pounraja
- Web page: https://patentgrep.com/patent/US20240189456A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 14/47: from mammals
- C12N 15/861: Adenoviral vectors
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2750/14141: Use of virus, viral particle or viral elements as a vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods of treating subjects having a prion disease or at risk of developing a prion disease by administering a nucleic acid molecule encoding a modified Prion protein (PrP), and methods of identifying a subject that is a candidate for treatment or prevention of a prion disease are presented herein.

## Claims

### Claim 1

A method of treating a subject having a prion disease or at risk of developing a prion disease, the method comprising:
a) administering a nucleic acid molecule encoding a modified Prion protein (PrP) to the subject; or
b) administering an inhibitory nucleic acid molecule that that targets a region of a prion nucleic acid molecule (PRNP) that comprises a genetic variation that causes production of a scrapie PrP to the subject;
wherein the subject comprises at least one reference PRNP allele or comprises at least one PRNP allele encoding an endogenous scrapie PrP;
wherein the nucleic acid molecule encoding the modified PrP administered to the subject comprises a nucleotide sequence encoding PrP but having a deletion that comprises 24 nucleotides within the nucleotide sequence encoding the octapeptide repeat region.

### Claim 2 (depends on 1)

The method of claim 1, wherein the 24 nucleotide deletion within the nucleotide sequence encoding the octapeptide repeat region is within the R2 to R4 region.

### Claim 3 (depends on 1)

The method of claim 1, wherein the 24 nucleotide deletion within the nucleotide sequence encoding the octapeptide repeat region is within the R3 to R4 region.

### Claim 4 (depends on 1)

The method of claim 1, wherein the nucleic acid molecule encoding the modified PrP administered to the subject comprises a nucleotide sequence encoding PrP but having a deletion that comprises 24 nucleotides and comprises the deletion of ACAGCCT within the nucleotide sequence encoding the octapeptide repeat region.

### Claim 5 (depends on 1)

The method of claim 1, wherein the nucleic acid molecule encoding the modified PrP administered to the subject comprises a nucleotide sequence encoding PrP but having a deletion of ACAGCCTCATGGTGGTGGCTGGGG (SEQ ID NO: 3) or having a deletion of CATGGTGGTGGCTGGGGACAGCCT (SEQ ID NO: 4) within the nucleotide sequence encoding the octapeptide repeat region of PrP.

### Claim 6 (depends on 1)

The method of claim 1, wherein the endogenous scrapie PrP comprises P84S, P102L, P105L, P105S, P105T, G114V, A117V, G127V, M129V, G131V, S132I, A133V, Y145X, R148H, Q160X, Y163X, D167G, D167N, V176G, D188Efs25X, D178N-129V, D178N-129M, V180I, T183A, H187R, T188R, T188K, T188A, T193I, K194E, E196K, F198S, F198V, E200K, E200G, D202N, D202G, V203I, R208H, V210I, E211D, E211Q, Q212P, I215V, Q217R, Y218N, E219K, A224V, Y226X, Q227X, M232R, P238S, 2-0PRD, 2-0PRI, 3-OPRI, 4-OPRI, 5-OPRI, 6-OPRI, 7-OPRI, 8-OPRI, 9-OPRI, or 12-OPRI.

### Claim 7 (depends on 1)

The method of claim 1, wherein the endogenous scrapie PrP comprises V180I, E200K, or V210I.

### Claim 8 (depends on 1)

The method of claim 1, wherein the endogenous scrapie PrP comprises E200K.

### Claim 9 (depends on 1)

The method of claim 1, wherein the nucleic acid molecule encoding the modified PrP is administered to the subject by a vector to achieve episomal expression of the modified PrP.

### Claim at position 10

10-11. (canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein the nucleic acid molecule encoding the modified PrP administered to the subject is inserted into the genome of the subject at the prion promoter site or a different site in the genome of the subject.

### Claim at position 12

13-15. (canceled)

### Claim 16 (depends on 1)

The method of claim 1, wherein the prion disease is familial Creutzfeldt-Jakob disease (CJD), sporadic CJD, variant CJD, iatrogenic CJD, Gerstmann-Straussler-Scheinker (GSS) syndrome, fatal familial insomnia (FFI), prion protein amyloidosis, systemic amyloidosis, or prion protein cerebral amyloid angiopathy.

### Claim at position 14

17-19. (canceled)

### Claim 20

A method of treating a subject having a prion disease or at risk of developing a prion disease by administering a nucleic acid molecule encoding a modified Prion protein (PrP) to the subject, the method comprising:
determining or having determined whether the subject comprises at least one reference PRNP allele or comprises at least one PRNP allele encoding an endogenous scrapie PrP, by:
obtaining or having obtained a biological sample from the subject; and
performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising at least one reference PRNP allele or comprising at least one PRNP allele encoding an endogenous scrapie PrP; and
administering or continuing to administer the nucleic acid molecule encoding the modified PrP to the subject that has at least one reference PRNP allele or has at least one PRNP allele encoding an endogenous scrapie PrP;
wherein the nucleic acid molecule encoding the modified PrP administered to the subject comprises a nucleotide sequence encoding PrP but having a deletion that comprises 24 nucleotides within the nucleotide sequence encoding the octapeptide repeat region; and
wherein the presence of at least one reference PRNP allele or at least one PRNP allele encoding an endogenous scrapie PrP indicates the subject has an increased risk of developing a prion disease compared to a subject that is homozygous for a PRNP allele encoding PrP but having a deletion that comprises 24 nucleotides within the nucleotide sequence encoding the octapeptide repeat region.

### Claim 21 (depends on 20)

The method of claim 20, wherein the nucleic acid molecule encoding the modified PrP administered to the subject comprises a nucleotide sequence encoding PrP but having a deletion that comprises 24 nucleotides within the nucleotide sequence encoding the R2 to R4 region of the octapeptide repeat region.

### Claim 22 (depends on 20)

The method of claim 20, wherein the nucleic acid molecule encoding the modified PrP administered to the subject comprises a nucleotide sequence encoding PrP but having a deletion that comprises 24 nucleotides within the nucleotide sequence encoding the R3 to R4 region of the octapeptide repeat region.

### Claim 23 (depends on 20)

The method of claim 20, wherein the nucleic acid molecule encoding the modified PrP administered to the subject comprises a nucleotide sequence encoding PrP but having a deletion that comprises 24 nucleotides and comprises the deletion of ACAGCCT within the nucleotide sequence encoding the octapeptide repeat region.

### Claim 24 (depends on 20)

The method of claim 20, wherein the nucleic acid molecule encoding the modified PrP administered to the subject comprises a nucleotide sequence encoding PrP but having a deletion of ACAGCCTCATGGTGGTGGCTGGGG (SEQ ID NO: 3) or having a deletion of CATGGTGGTGGCTGGGGACAGCCT (SEQ ID NO: 4) within the nucleotide sequence encoding the octapeptide repeat region of PrP.

### Claim 25 (depends on 20)

The method of n m claim 20, wherein the endogenous scrapie PrP comprises P84S, P102L, P105L, P105S, P105T, G114V, A117V, G127V, M129V, G131V, S132I, A133V, Y145X, R148H, Q160X, Y163X, D167G, D167N, V176G, D188Efs25X, D178N-129V, D178N-129M, V180I, T183A, H187R, T188R, T188K, T188A, T193I, K194E, E196K, F198S, F198V, E200K, E200G, D202N, D202G, V203I, R208H, V210I, E211D, E211Q, Q212P, I215V, Q217R, Y218N, E219K, A224V, Y226X, Q227X, M232R, P238S, 2-0PRD, 2-OPRI, 3-OPRI, 4-OPRI, 5-OPRI, 6-OPRI, 7-OPRI, 8-OPRI, 9-OPRI, or 12-OPRI.

### Claim 26 (depends on 20)

The method of claim 20, wherein the endogenous scrapie PrP comprises V180I, E200K, or V210I.

### Claim 27 (depends on 20)

The method of claim 20, wherein the endogenous scrapie PrP comprises E200K.

### Claim 28 (depends on 20)

The method of claim 20, wherein the nucleic acid molecule encoding the modified PrP is administered to the subject by a vector to achieve episomal expression of the modified PrP.

### Claim at position 24

29-30. (canceled)

### Claim 31 (depends on 20)

The method of claim 20, wherein the nucleic acid molecule encoding the modified PrP administered to the subject is inserted into the genome of the subject at the prion promoter site or a different site in the genome of the subject.

### Claim at position 26

32-34. (canceled)

### Claim 35 (depends on 20)

The method of claim 20, wherein the prion disease is familial Creutzfeldt-Jakob disease (CJD), sporadic CJD, variant CJD, iatrogenic CJD, Gerstmann-Straussler-Scheinker (GSS) syndrome, fatal familial insomnia (FFI), prion protein amyloidosis, systemic amyloidosis, or prion protein cerebral amyloid angiopathy.

### Claim at position 28

36-38. (canceled)

### Claim 39

A method of identifying a subject that is a candidate for treatment or prevention of a prion disease, the method comprising:
determining or having determined whether the subject comprises at least one reference PRNP allele or comprises at least one PRNP allele encoding an endogenous scrapie PrP, by:
obtaining or having obtained a biological sample from the subject; and
performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising at least one reference PRNP allele or comprising at least one PRNP allele encoding an endogenous scrapie PrP; and
wherein the presence of at least one reference PRNP allele or at least one PRNP allele encoding an endogenous scrapie PrP indicates the subject has an increased risk of developing a prion disease compared to a subject that is homozygous for a PRNP allele encoding PrP but having a deletion that comprises 24 nucleotides within the nucleotide sequence encoding the octapeptide repeat region, and is a candidate for treatment or prevention.

### Claim 40 (depends on 39)

The method of claim 39, wherein the endogenous scrapie PrP comprises P84S, P102L, P105L, P105S, P105T, G114V, A117V, G127V, M129V, G131V, S132I, A133V, Y145X, R148H, Q160X, Y163X, D167G, D167N, V176G, D188Efs25X, D178N-129V, D178N-129M, V180I, T183A, H187R, T188R, T188K, T188A, T193I, K194E, E196K, F198S, F198V, E200K, E200G, D202N, D202G, V203I, R208H, V210I, E211D, E211Q, Q212P, I215V, Q217R, Y218N, E219K, A224V, Y226X, Q227X, M232R, P238S, 2-0PRD, 2-0PRI, 3-OPRI, 4-OPRI, 5-OPRI, 6-OPRI, 7-OPRI, 8-OPRI, 9-OPRI, or 12-OPRI.

### Claim 41 (depends on 39)

The method of claim 39, wherein the endogenous scrapie PrP comprises V180I, E200K, or V210I.

### Claim 42 (depends on 39)

The method of claim 39, wherein the endogenous scrapie PrP comprises E200K.

### Claim 43 (depends on 39)

The method of claim 39, wherein the prion disease is familial Creutzfeldt-Jakob disease (CJD), sporadic CJD, variant CJD, iatrogenic CJD, Gerstmann-Straussler-Scheinker (GSS) syndrome, fatal familial insomnia (FFI), prion protein amyloidosis, systemic amyloidosis, or prion protein cerebral amyloid angiopathy.

### Claim at position 34

44-46. (canceled)

### Claim 47 (depends on 39)

The method of claim 39, the method further comprising administering to a subject that is a candidate for treatment or prevention a nucleic acid molecule encoding a modified PrP that comprises a nucleotide sequence encoding PrP but having a deletion that comprises 24 nucleotides within the nucleotide sequence encoding the octapeptide repeat region.

### Claim at position 36

48-58. (canceled)

### Claim 59

A nucleic acid molecule encoding a modified Prion protein (PrP) that comprises a nucleotide sequence encoding PrP but having a deletion that comprises 24 nucleotides within the nucleotide sequence encoding the octapeptide repeat region.

### Claim at position 38

60-75. (canceled)
